1. Home
  2. EAF vs SWKH Comparison

EAF vs SWKH Comparison

Compare EAF & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GrafTech International Ltd.

EAF

GrafTech International Ltd.

HOLD

Current Price

$9.75

Market Cap

236.5M

Sector

Energy

ML Signal

HOLD

Logo SWK Holdings Corporation

SWKH

SWK Holdings Corporation

HOLD

Current Price

$16.70

Market Cap

198.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
EAF
SWKH
Founded
1886
1996
Country
United States
United States
Employees
N/A
9
Industry
Industrial Machinery/Components
Diversified Financial Services
Sector
Energy
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
236.5M
198.4M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
EAF
SWKH
Price
$9.75
$16.70
Analyst Decision
Hold
Strong Buy
Analyst Count
5
1
Target Price
$11.75
$18.00
AVG Volume (30 Days)
252.7K
104.8K
Earning Date
05-01-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$504,134,000.00
N/A
Revenue This Year
$4.25
N/A
Revenue Next Year
$12.49
N/A
P/E Ratio
N/A
$9.18
Revenue Growth
N/A
N/A
52 Week Low
$0.93
$13.86
52 Week High
$20.32
$17.90

Technical Indicators

Market Signals
Indicator
EAF
SWKH
Relative Strength Index (RSI) 59.59 32.19
Support Level $7.78 $14.69
Resistance Level $9.78 $17.08
Average True Range (ATR) 0.69 0.37
MACD 0.04 -0.05
Stochastic Oscillator 69.85 12.06

Price Performance

Historical Comparison
EAF
SWKH

About EAF GrafTech International Ltd.

GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products used as raw material in the production of graphite electrodes.

About SWKH SWK Holdings Corporation

SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

Share on Social Networks: